Accreditation Information
Jointly provided by Partners for Advancing Clinical Education (PACE) and Bio Ascend LLC.
Target Audience
This activity is intended for oncologists, hematologists, pathologists, clinical scientists, nurse practitioners, physician assistants, nurses, and pharmacists charged with the care of patients with lung cancer.
Learning Objectives
- Describe the importance of either tissue or liquid molecular testing before starting the first-line treatment of patients with NSCLC
- Assess the safety and efficacy of current and emerging therapeutic approaches for the treatment of patients with lung cancer, including modalities such as traditional chemotherapy, radiotherapy, molecularly targeted agents, immunotherapy, and others
- Evaluate strategies to minimize and manage treatment-related adverse events that may occur during the treatment of patients with NSCLC
- Create protocols to foster participation in clinical trials from both clinicians and patients with lung cancer in order to introduce novel agents into practice that improve the outcomes of patients with these malignancies
Disclosure of Conflicts of Interest
PACE requires planners, faculty, and others who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
Disclosures
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are
organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.
Faculty disclosure listings coming soon!
| Faculty | Conflicts of Interest |
|---|---|
| Valsamo Anagnostou, MD, PhD | Coming Soon |
| Fatemeh Ardeshir, MD, MSc | No relevant financial relationships to disclose |
| Ioana Bonta, MD | Advisory Board: AstraZeneca, Daiichi-Sankyo, Jensen Scientific Consulting: Roche |
| Julie Brahmer, MD | Consulting: AstraZeneca, RAPT Therapeutics, Mestag, GSK Research Funding: AstraZeneca, BMS DSMB: Genmab |
| Paul Bunn, MD | Independent Contractor: Bristol Myers Squibb, Daiichi-Sankyo, Merck, Verastem Consultant, Advisor, Speaker: AstraZeneca, Lilly |
| Jennifer Carlisle, MD | Consultant, Advisor, Speaker: Amgen, Catalyst Researcher: Chipscreen Biosciences, Clinigen, Genentech, Hutchmed, Inhibrix |
| Jamie E. Chaft, MD | Consultant, Advisor, Speaker: AstraZeneca, Boehringer-Ingelheim, Bristol Myers Squibb, Genentech, Guardant Health, Janssen, Lilly, Merck, Sanofi-Regeneron Independent Contractor: Lilly |
| Shirish M. Gadgeel, MD | Advisory Board: AstraZeneca, , AbbVie, Amgen, Bristol Myers Squibb, Daiichi-Sankyo, Ellipses Pharma, Genentech, Gilead, Johnson & Johnson, Pfizer, Regeneron, Travel: Merck |
| Ryan Gentzler, MD | Researcher: Pfizer, Nalo Therapeutics, Puma, Mirati, Dizal, Chugai, Amgen, AstraZeneca, Janssen, Daiichi Sankyo |
| Harpaul (Paul) Gill, MD | No relevant financial relationships to disclose |
| John Heymach, MD, PhD | No relevant financial relationships to disclose |
| William Jonas, MD | No relevant financial relationships to disclose |
| Onkar Khullar, MD, MSc | No relevant financial relationships to disclose |
| Mohan Krishnamachary, MD | Coming Soon |
| Ticiana A. Leal, MD | Consultant, Advisor, Speaker: AbbVie, Amgen, AstraZeneca, Black Diamond, Bristol Myers Squibb, Catalyst, Daiichi-Sankyo, Eisai, Gilead, Janssen, Jazz, Merck, Novartis, Pfizer, Regeneron, Roche/Genentech, Takeda |
| Steven McCune, MD, PhD | Consultant, Advisor, Speaker: AbbVie, AstraZeneca, Bristol Myers Squibb |
| Taofeek Owonikoko, MD, PhD | Coming Soon |
| Suresh Ramalingam, MD, FACP, FASCO | Coming Soon |
| Karen L. Reckamp, MD | Consultant, Advisor, Speaker: Amgen, AstraZeneca, Blueprint Medicines, Daiichi Sankyo, EMD Serono, Genentech, GlaxoSmithKline, Janssen, Lilly, Novocure, Mirati Researcher: Genentech, Blueprint Medicines, Calithera, Daiichi Sankyo, Elevation Oncology, Janssen |
| Gregory Riely, MD | Researcher: BMS, Lilly, Pfizer, Amgen, Roche Consultant, Advisor, Speaker: Novartis |
| Conor Steuer, MD | Consultant, Advisor, Speaker: Daiichi Sankyo, Boehringer-Ingelheim |
| Sibo Tian, MD | Other (FLASH-RT Research Funding): Varian Medical Systems Consultant, Advisory, Speaker: Bio Ascend, Genentech, Merck (via RTOG Foundation) Employee: Emory University |
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Bio Ascend LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Education
PACE designates this live activity for a maximum of 6 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Upon successfully completing the post-test with a passing score of 75% or better and activity evaluation, your certificate will be made available immediately. By selecting ABIM MOC credit, you are giving the providers permission to collect and submit the required individual learner completion data for the selected certifying boards via PARS.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Americans with Disabilities Act
Event staff will be glad to assist you with any special needs (i.e., physical, dietary, etc). Please contact atllung@bioascend.com prior to the live event.
How To Claim Credit
Details coming soon!